people
  • Overview
  • Grant Central
    Find funding & collaboration opportunities, and coordinate proposal development.
  • Medvane
    View biomedical research & publication trends within the Harvard community.
  • Harvard Catalyst Profiles
    Contact, publication, and social network information about Harvard faculty and fellows.
  • Research Navigators
    Scientific liaisons who facilitate clinical and translational research.
learning
resources

Medvane

The present state and historical trends of biomedical research in the Harvard community.

Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010

Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Adiponectin is an adipose tissue-secreted endogenous insulin sensitizer, which plays a key role as a mediator of peroxisome proliferator-activated receptor gamma action. Adiponectin alters glucose metabolism and insulin sensitivity, exhibits antiinflammatory and antiatherogenic properties, and has been linked to several malignancies. Circulating concentrations of adiponectin are determined primarily by genetic factors, nutrition, exercise, and abdominal adiposity. Adiponectin concentrations are lower in subjects with obesity, metabolic syndrome, and cardiovascular disease. Adiponectin knockout mice manifest glucose intolerance, insulin resistance, and hyperlipidemia and tend to develop malignancies especially when on high-fat diets. Animal studies have also shown beneficial effects of adiponectin in rodents in vivo. Circulating concentrations of adiponectin are lower in patients with diabetes, cardiovascular disease, and several malignancies. Studies to date provide promising results for the diagnostic and therapeutic role of adiponectin in obesity, insulin resistance, diabetes, cardiovascular disease, and obesity-associated malignancies.
See PubMed record in a new window